Workstream Type: Data Analysis

  • Xeljanz, the FDA, and nine years of patient harm

  • Atypical antipsychotics: Decades of use, unfathomable harms

  • Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

  • Curbing Biologic Drug Spending with P-quad

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • Bottom-Up Pricing Estimate for P-quad

  • Modeling P-quad

  • Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students

  • Research on the current state of US drug pricing and its effects

  • Analysis of Medicare Part D Plans Shows $9B Upcharge